BioSpace News Archive

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announces its 2022 third quarter business results.

LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and analysis provider to the life sciences market, announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis.

Cerevance today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.

Immunovant, Inc. today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th -15th , 2022.

TransCode Therapeutics, Inc. today announced that it will be presenting at the Sidoti Virtual Conference.

Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting.

Nykode Therapeutics ASA announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present and host 1x1 meetings at two upcoming investor conferences in November.

Calliditas Therapeutics AB announced that it will host a Key Opinion Leader Fireside Chat on the IgA Nephropathy treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.

Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

Tessa Therapeutics Ltd. announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine.